Research Article

Real-World Three-Year Clinical Outcomes of Biolimus-Eluting Stents versus Other Contemporary Drug-Eluting Stents in Patients with Acute Myocardial Infarction Patients: Data from the Korea Acute Myocardial Infarction Registry (KAMIR)

Table 2

Clinical outcomes of acute myocardial infarction patients with preserved left ventricular systolic function according to the use of DES type during a 3-year follow-up.

VariablesEntire populationIPTW weighted population
BES (n = 2020)ZES (n = 2446)EES (n = 5293) valueBES (n = 6036)ZES (n = 5795)EES (n = 7936) value

MACE303 (15.0)415 (16.9)988 (18.6)0.001959 (15.8)1017 (17.5)1446 (18.2)0.001
TLF127 (6.2)204 (8.3)500 (9.4)<0.001393 (6.5)472 (8.1)730 (9.1)<0.001
Total death141 (6.9)201 (8.2)526 (9.9)<0.001436 (7.2)499 (8.6)761 (9.5)<0.001
Cardiac death82 (4.0)133 (5.4)361 (6.8)<0.001253 (4.1)312 (5.3)525 (6.6)<0.001
Recurrent MI44 (2.1)69 (2.8)168 (3.1)0.073102 (1.6)152 (2.6)254 (3.2)<0.001
 STEMI9 (0.4)12 (0.4)45 (0.8)0.07321 (0.3)17 (0.2)64 (0.8)<0.001
 NSTEMI35 (1.7)58 (2.3)123 (2.3)0.25581 (1.3)139 (2.3)191 (2.4)<0.001
Revascularization162 (8.0)213 (8.7)453 (8.5)0.685527 (8.7)510 (8.8)670 (8.4)0.724
 TLR46 (2.2)71 (2.9)138 (2.6)0.427142 (2.3)142 (2.4)204 (2.5)0.710
 TVR93 (4.6)108 (4.4)243 (4.5)0.934294 (4.8)244 (4.2)363 (4.5)0.226
 Non-TVR79 (3.9)110 (4.4)219 (4.1)0.606263 (4.3)272 (4.6)319 (4.0)0.156
Stent thrombosis10 (0.4)10 (0.4)27 (0.5)0.83223 (0.3)32 (0.5)40 (0.5)0.375

IPTW, inverse probability of treatment weighting; BES, biolimus-eluting stent; EES, everolimus-eluting stent; ZES, zotarolimus-eluting stent; MACE, major adverse cardiac event, the composite of total death, recurrent MI and revascularization; TLF, target lesion failure, composite of cardiac death, recurrent MI, and TLR; MI, myocardial infarction; STEMI, ST-elevation myocardial infarction; NSTEMI, non-ST-elevation myocardial infarction; TLR, target lesion revascularization; TVR, target vessel revascularization.